This is where I become most insistent with patients, because it is where the most money is wasted. When I assess a device — for a patient, or as a clinician evaluating what to stand behind — I do not look at reviews or before-and-after photographs first. I look for two layers of standards: the technical parameters and the legal certification. A device should satisfy both.
Wavelength: 630–680 nm (typically 650 / 655 / 678 nm)Effective dose: ≈ 3–5 J/cm²Laser safety class: Class 3RSession: ~12–25 min, around 3× weeklyRealistic horizon: 16–40 weeksDose control: fixed timer + sensors
The wavelength must sit inside the optical window. The dose must be controlled and sit in the effective range — neither so low it does nothing nor so high it crosses into the suppressive zone of the biphasic curve. Laser-containing devices should be appropriately classified for eye safety; most hair devices fall under Class 3R, with engineering safeguards. And the better devices add sensors: a contact sensor that only allows the device to operate when correctly positioned on the scalp, and a thermal sensor that guards against any unexpected heating. These are not gimmicks; they are how a device guarantees it is delivering the intended dose to the intended target, every session.
This is the part that genuinely confuses people, and where dishonest marketing thrives. "FDA approved," "CE marked," "clinically proven" — these phrases are thrown around loosely and mean very different things in different markets. Here is the accurate picture.
| Market | The standard that matters | What it actually means |
|---|---|---|
| European Union / France | CE under MDR 2017/745, Class IIa | A genuine medical device, assessed by an independent Notified Body, with a technical file, a clinical evaluation and ongoing post-market surveillance. In the EU these devices are medical devices — not cosmetics — and the MDR is considerably more demanding than the directive it replaced. |
| United Kingdom (GB) | UKCA, or accepted CE marking, registered with the MHRA | Post-Brexit, Great Britain currently continues to accept EU MDR CE-marked devices under transitional arrangements through to 30 June 2030, while the UKCA route also exists. The MHRA is consulting on recognising CE marking indefinitely. Non-UK makers must appoint a UK Responsible Person and register with the MHRA. Northern Ireland continues to follow EU rules. |
| United States | FDA 510(k) clearance, Class II | Note the word: clearance, not approval. It means the device was shown to be substantially equivalent in safety and effectiveness to a device already on the market — not that it underwent the extensive trials of an "approved" drug. Indications are usually limited to defined Norwood (men) and Ludwig-Savin (women) loss patterns and lighter Fitzpatrick skin types. |
| Manufacturing quality | ISO 13485 & ISO 14971 | The international standards for a medical-device quality management system and for systematic risk management. A manufacturer that holds these is operating as a medical-device company, not a gadget assembler. |
| Electrical & laser safety | IEC 60601 & IEC 60825 | The standards governing the safety of medical electrical equipment and the classification and safe use of laser products, respectively. |
The most common — and most expensive — misunderstanding
"FDA cleared" is not "FDA approved," and neither one makes a device legal to sell in Europe or the UK. A US clearance says nothing about European compliance. For France and the EU, the standard you must see is CE under MDR, Class IIa. A device proudly waving an American clearance while quietly lacking European medical-device certification is a device sold to you under a different — and lower — bar than the one your market actually requires.
I have spent most of this article describing what a credible light device must be: the right wavelength, a controlled dose, intelligent sensors, honest indications, and certification matched to the market it is sold in. I will be transparent about why those criteria are written so precisely. They are the brief we set ourselves when we built our own.
LOREW · Clinical Technology, Surgically EngineeredLOREW TECHClinical light technology, surgically engineered.
LOREW TECH is our clinical-technology house — a brand engineered by a surgeon, not assembled by a marketer. Where most hair-device companies are either faceless electronics manufacturers with no clinical authority, or cosmetic houses with no engineering, LOREW TECH is built deliberately at the intersection: medical-grade photonics designed by people who restore hair surgically for a living.
Our scalp device was engineered to the exact standards set out in this article: a clinically validated wavelength inside the 630–680 nm optical window, a fixed therapeutic dose to respect the biphasic curve, and contact and thermal sensors that hold every session inside the effective range. It is designed for the French and European market around CE MDR 2017/745 Class IIa requirements — a medical device, not a cosmetic — and held to the very standard you have just read about.
This is photonic technology with a clinical conscience: parameters you can verify, claims we will not inflate, and indications we state honestly. That is the whole point of a surgeon-led technology brand.
630–680 nm validated windowFixed therapeutic doseContact + thermal sensorsDesigned to CE MDR Class IIaSurgeon-engineered
Armed with the science, you can now read a product page the way a clinician does. Here is the checklist I give patients, followed by the warning signs that should make you close the tab.
Because I am a surgeon, patients sometimes expect me to dismiss non-surgical tools. The opposite is true. The best long-term outcomes I see come from treating hair loss as the chronic, progressive condition it is — with a layered plan, of which surgery is only one possible layer. Light therapy earns a place in that plan in three specific situations.
Before surgery, or instead of it, in early loss. A patient in the early stages of pattern loss is often not yet a surgical candidate. Here, the goal is to defend the existing hair and slow the progression — buying time, preserving density, and sometimes deferring an operation for years. Photobiomodulation, usually alongside medical therapy, is a reasonable and low-risk part of that defensive strategy.
After a hair transplant. Surgery relocates follicles, but it does nothing to protect the patient's surrounding native hair, which remains genetically susceptible and continues to thin. This is the classic reason a transplant can look thinner years later — not because the grafts failed, but because the untransplanted hair around them was lost. A maintenance plan, which can include light therapy, helps protect that native hair and preserve the overall result. Some clinicians also use PBM to support the recovering scalp environment in the months after the procedure.
As a combination partner. As the evidence on synergy with minoxidil shows, light works best stacked with other modalities rather than relied upon alone. In practice, a typical plan I might discuss could combine a medical therapy, a light device, and good scalp and general health — each contributing a fraction, together adding up to a result none would achieve alone.
What light therapy is not is a way to avoid facing the reality of advanced loss. If a patient has lost the follicles across the crown or hairline, no amount of light will regrow them, and I will say so directly. Pretending otherwise would not be kindness; it would be selling false hope, which is the opposite of medicine.
Even the best-engineered device fails if used badly, and the most common failure is not technical — it is human. People start enthusiastically, see nothing in a few weeks, and quietly stop. So if you commit to a device, commit to the protocol.
Can a laser or LED device replace a hair transplant?
No. These devices stimulate follicles that are still alive but weakening; they can slow shedding and improve the quality of existing hair. They cannot create hair where the follicle is already gone. For advanced, established baldness, the only permanent restoration is transplantation of living follicles. Light therapy's role is in protection and support — before surgery, after it, and alongside medical treatment — not as a replacement for it.
How long before I see results?
Expect to measure progress in months. Because the device acts on the hair cycle, meaningful change usually begins after roughly sixteen weeks, with the fuller picture emerging over nine to ten months of consistent use. Consistency is the most important variable, and if you stop using the device, gains gradually reverse because the underlying condition is ongoing.
Is a more powerful device better?
Not necessarily — and possibly the opposite. Photobiomodulation follows a biphasic dose response: beyond an optimal point, more energy stops helping and can suppress the response. What matters is the correct dose, delivered evenly across the whole treatment area, every session. A fixed, automatically timed protocol is a sign of good engineering, not a limitation.
Can it be used with minoxidil or finasteride?
Yes, and it is generally encouraged. The evidence consistently shows that light therapy enhances the effect of topical minoxidil, because the two work through different mechanisms. The best results come from a coherent, layered plan supervised by a clinician — not from any single product used in isolation.
Is light therapy safe? Does it have side effects?
At the correct wavelength and a controlled, non-thermal dose, it is considered very safe, which is part of its appeal. The most commonly reported effects are mild and temporary — slight scalp dryness or transient redness. The important exceptions are people taking medication that increases light sensitivity, or with significant systemic conditions, who should seek individual medical advice before starting.
Does "FDA cleared" mean a device is safe and legal for me?
It depends entirely on where you live. "FDA cleared" is a US designation meaning the device was found substantially equivalent to one already on the market — it is not the same as "approved," and it carries no legal weight in Europe or the UK. For France and the EU, the standard to look for is CE marking under the Medical Device Regulation (MDR), Class IIa. Always match the certification to your own market.
Does it work for women?
Yes. Female-pattern hair loss involves the same follicular miniaturisation process, and women with early-to-moderate diffuse thinning are often good candidates for light therapy, frequently as part of a broader plan. As always, a proper diagnosis comes first, because hair loss in women can have several causes that require different treatment.
Who is NOT a good candidate?
Anyone with advanced loss where the follicles are gone, who is hoping for regrowth in those areas; anyone expecting a quick fix in weeks; and anyone unwilling to commit to consistent use over many months. Light therapy rewards the patient and the disciplined, and frustrates those looking for an effortless miracle.
Light therapy, medical treatment, or a transplant — the right combination is personal, and it begins with an honest diagnosis. At Hairmedico, every case is planned individually, surgeon-led, on a one-patient-per-day model.
Medical disclaimer: This article is for general information and education. It is not personal medical advice and does not replace consultation with a qualified clinician. The type, cause and stage of hair loss vary between individuals, and treatment should be chosen on the basis of an individual diagnosis. Efficacy data referenced reflects published clinical trials and meta-analyses; individual results vary. Regulatory information is summarised for general understanding and may change — verify current requirements for your market before purchasing a medical device.
At-home laser caps and LED helmets have moved from gimmick to genuine clinical tool. But the gap between a device that works and one that wastes your time is enormous — and it is decided not by marketing, but by physics, biology and regulation. Here is everything a patient (and an honest clinician) should understand.
By Dr Arslan Musbeh, ISHRS-Certified Hair Transplant SurgeonHairmedico Istanbul~22 min read
There is a sentence I hear in consultation almost every week. A patient sits down, takes out their phone, and shows me a laser cap they bought online. "I've been wearing this for three months," they say. "Is it doing anything?" The honest answer is rarely a clean yes or no. A correctly chosen, properly engineered device, used with discipline, can measurably support the hair follicle. A device that ignores the science is, at best, an expensive way to warm your scalp. The whole of this article is about how to tell the two apart — and why, as a surgeon who restores hair for a living, I take light therapy seriously without ever overselling it.
Light-based hair devices sit in an unusual place. They are sold like consumer gadgets, marketed like cosmetics, and yet — when built correctly — they are genuinely medical devices governed by the same regulatory frameworks as the equipment in a hospital. That tension is the source of most of the confusion patients carry. So let us start not with the device, but with the problem it is trying to solve.
To understand whether light can help, you first have to understand what is going wrong. The overwhelming majority of hair loss I see — in men and increasingly in women — is androgenetic alopecia, often called male- or female-pattern hair loss. It is not a disease of the hair itself, but of the follicle's response to hormones over time.
Each hair follicle cycles continuously through three phases: a long growth phase (anagen), a brief transition phase (catagen), and a resting phase (telogen) after which the hair sheds and the cycle restarts. In a healthy scalp, the great majority of follicles are in anagen at any given moment, which is why density looks stable. Androgenetic alopecia disrupts this balance.
In genetically susceptible follicles, the hormone dihydrotestosterone (DHT) — a derivative of testosterone produced by the enzyme 5-alpha-reductase — binds to receptors in the follicle and progressively shortens the anagen phase. With each cycle, the follicle spends less time growing and more time resting. The hair it produces becomes finer, shorter and lighter: a process called miniaturisation. Over years, a thick terminal hair shrinks toward a barely visible vellus hair, and eventually the follicle may stop producing a meaningful shaft at all.
This is the crucial concept for everything that follows. Hair loss in androgenetic alopecia is, for a long time, a story of weakening rather than death. The follicles are still present, still alive, still cycling — just doing so more weakly with each pass. That window, where the machinery still exists but is underperforming, is precisely where photobiomodulation has something to offer. Once a follicle is truly gone — its dermal papilla exhausted, the unit fibrosed — no light, lotion or supplement will bring it back. Only transplantation of living follicles from a donor area can restore hair there. Understanding this boundary is what separates a realistic treatment plan from false hope.
"Hair loss, for a long time, is a story of weakening rather than death. That window is exactly where light therapy can act."
The story of light therapy for hair begins, fittingly, by accident. In the late 1960s, a Hungarian physician named Endre Mester set out to test whether laser light could induce cancer in mice. He shaved the animals, applied a low-powered ruby laser, and waited. The lasers were far weaker than he believed — and the tumours never came. Instead, he noticed something he had not been looking for: the shaved fur on the treated mice grew back faster than on the untreated controls. What began as a failed cancer experiment became the first observation of what we now call photobiomodulation.
For decades the field was held back by inconsistent terminology and overblown claims. It was variously called low-level laser therapy (LLLT), cold laser, soft laser and biostimulation — names that did the science no favours, because they invited both quackery and dismissal in equal measure. The modern, preferred term is photobiomodulation (PBM), because it captures the truth more precisely: light at the right parameters does not heat or cut tissue, it modulates cellular behaviour.
The turning point for hair specifically came when regulators began clearing dedicated devices and when better-designed clinical trials replaced anecdote. Over the past fifteen years, the combination of plausible mechanism, accumulating randomised evidence and regulatory recognition has moved PBM from the fringe into mainstream trichology. It is now routinely discussed alongside minoxidil and finasteride as part of the medical management of pattern hair loss — not as a replacement for them, but as a complement.
This is the part most articles skip, and it is the part that matters most, because the mechanism dictates the standards. Let us go slowly.
Not all light penetrates skin equally. Short wavelengths (blue, green) are absorbed within the first fraction of a millimetre and never reach the hair bulb. Very long wavelengths scatter and dissipate as heat. There is a relatively narrow band — roughly 630 to 680 nanometres in the red, extending into the near-infrared — often called the "optical window," where light penetrates deeply enough to reach the dermal structures that house the follicle without being absorbed wastefully by water or melanin along the way. This is not a marketing preference; it is the physical reason credible hair devices cluster around 650, 655 and 678 nm. Serious scientific reviews explicitly exclude devices operating below 600 nm or above 950 nm, because the light cannot do the required job.
Once red light reaches the follicle, it is absorbed by a specific molecule inside the cell's mitochondria — the enzyme cytochrome c oxidase, the fourth complex in the respiratory chain that produces the cell's energy. Cytochrome c oxidase is what scientists call a chromophore: a molecule that captures light of particular wavelengths. When red photons are absorbed here, several things happen in sequence:
Translated from the cellular level to the scalp, the intended effects are: prolonging the anagen growth phase so follicles spend more time producing hair; encouraging miniaturised follicles to produce thicker shafts; and dampening the low-grade inflammation that often accompanies pattern hair loss. Importantly, none of this is a heat effect. A correctly built device does not burn, sting or ablate — the energy delivered is far below any thermal threshold. The sensation is, in practical terms, nothing at all. If a device makes your scalp hot, that is a fault, not a feature.
Here is the single most important — and most commonly ignored — principle in this entire field. Photobiomodulation follows a biphasic dose response, sometimes described through the older Arndt-Schulz principle: a small dose stimulates, a moderate dose stimulates more, but beyond an optimal point, increasing the dose stops helping and can actively suppress the very response you wanted.
This is profoundly counter-intuitive for most patients, who reasonably assume that if a little light helps, more light, brighter light, or longer sessions must help more. With most consumer products that logic holds. With PBM it is wrong, and dangerously so for marketing purposes, because it means a device boasting enormous power output or extra-long sessions is not necessarily better — it may be worse, having sailed past the optimal dose into the suppressive zone.
The practical consequence is that dose control is the defining feature of a serious device. The relevant figure is not raw wattage but the energy delivered to a given area of scalp, measured in joules per square centimetre (J/cm²), with an effective therapeutic range commonly cited around 3 to 5 J/cm². A well-engineered device fixes this by combining a calibrated power output with an automatic, timed session length, so that the user cannot accidentally under- or over-dose. The presence of a fixed protocol — a device that simply switches off after its programmed session — is therefore a quality signal, not a limitation.
The clinician's translation
When a patient asks me "is a more powerful cap better?", my honest answer is: not necessarily, and possibly the opposite. What you want is the right dose delivered consistently to the whole treatment area — not the biggest number on the box. This is exactly the kind of nuance that marketing erases and engineering preserves.
Now to the question every patient actually wants answered: does it work? My answer, after years of integrating these tools into real treatment plans, is deliberately measured. Yes, in the right patients, with realistic expectations — but it is a meaningful boost, not a transformation, and certainly not a substitute for surgery in advanced loss.
26
Randomised controlled trials pooled in a 2025 network meta-analysis
1,638
Total participants across those trials
~80%
Reported clinical effectiveness in a 1,383-patient real-world study
The body of evidence has grown considerably and, importantly, much of it is reasonably well designed — that is, randomised and sham-controlled, where neither the patient nor the assessor knows whether the device they are using is the real one or a convincing dummy. This matters enormously in hair research, where expectation alone can colour subjective judgement.
Pooled analyses of these trials have repeatedly found a statistically significant increase in hair density in patients treated with photobiomodulation compared with sham devices. A 2025 network meta-analysis bringing together twenty-six randomised controlled trials in over sixteen hundred patients is among the most comprehensive to date, and it points in the same direction as earlier work: the effect is real and consistent. The magnitude is best described as moderate. It is enough to be visible and worthwhile, particularly in early-to-moderate loss, but it is not the kind of dramatic regrowth that transforms an advanced bald scalp.
Perhaps the most clinically useful finding concerns combination therapy. Several trials and reviews have examined what happens when light therapy is added on top of topical minoxidil, the workhorse of medical hair treatment. The consistent signal is synergy: the combination outperforms minoxidil alone. This fits neatly with the mechanism — minoxidil and light act through different pathways, so stacking them is additive rather than redundant. It is also why I almost never think of PBM as a stand-alone intervention. In my practice it is one instrument in an ensemble, not a soloist.
Integrity requires stating the caveats as plainly as the benefits. Trial designs vary in quality and length. Devices, wavelengths and dosing differ between studies, which makes direct comparison difficult. Most trials run for months, not years, so the very long-term picture is less certain. Response is also individual: some patients respond well, others modestly, a minority barely at all, and we cannot yet perfectly predict who will fall where. And crucially, every credible study is conducted in people with existing, living follicles — typically early-to-moderate pattern loss. There is no evidence, and no plausible mechanism, by which light regrows hair on skin where the follicles are already gone.
Patients agonise over this distinction, often because marketing tells them to. The truth is more nuanced than "laser good, LED bad."
Both LEDs and laser diodes can emit light in the therapeutic red band, and both target the same cellular switch. The difference lies in the quality of the light. A laser diode produces coherent (in-phase) and highly monochromatic (single-wavelength) light. Coherence and collimation allow laser light to penetrate the scalp more deeply and in a more focused, predictable way, which is one reason the bulk of the strongest clinical trial data comes from laser-based devices. An LED, by contrast, emits non-coherent light over a broader angle and a slightly wider band of wavelengths. It covers a larger surface area cheaply and runs cooler, but penetration depth and dose precision can be more variable.
In practice, the best modern devices are frequently hybrid: they pair laser diodes, for depth and dose precision over the densest areas, with LEDs, for broad and even coverage of the whole scalp. The label on the box matters far less than two underlying questions: is the light in the correct wavelength band, and is the correct dose being delivered evenly across the entire treatment area? A premium-sounding "laser helmet" with too few diodes leaving cold spots may underperform a well-distributed hybrid. Coverage and dose uniformity are the quiet engineering details that decide outcomes, and they never appear in advertising.
Beyond the light source, devices come in several form factors, each with trade-offs that affect not just comfort but, through the all-important variable of adherence, actual results.
I dwell on form factor because of a truth that the science makes unavoidable: the best device is the one you will actually use, correctly, for the better part of a year. A theoretically superior device that is too uncomfortable or too fiddly to use three times a week is, in real terms, inferior to a slightly less powerful device that fits seamlessly into a daily routine. Adherence is not a footnote to efficacy — it is a component of it.
FR
DE
RU
ES
PL
PT
IT
CS
AR
TR
Free Hair Analysis
Whatsapp